Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RLY-8161

Small molecule · Inhibitor of NRAS · developed by Relay Therapeutics

Phase 1 Most advanced trial
RLAY Developer
1 Registered trials

What is RLY-8161?

RLY-8161 is an orally bioavailable, NRAS-selective inhibitor that binds NRAS and inhibits its activity, suppressing NRAS-dependent signaling. It is being studied in advanced NRAS-mutant melanoma and other NRAS-mutant solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
NRAS
Mechanism
Inhibitor of NRAS
Pathways
NRAS-dependent signaling
Therapy area
Oncology
Developer
Relay Therapeutics, Inc. (RLAY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07584226 Phase 1/2 Advanced NRAS-Mutant Melanoma Recruiting RLAY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid TumorsNRAS G12DNRAS G12VNRAS G13DNRAS G13RNRAS MutationNRAS Q61HNRAS Q61KNRAS Q61LNRAS Q61R

More from Relay Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RLAY page.

Follow RLAY, the company behind RLY-8161

See RLAY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RLAY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.